{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:13:36Z","timestamp":1787015616975,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":1374,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sarcoid tumors are common in horses and may negatively impact the performance and value of the horse. No known treatment is reliably successful.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypotheses\/Objectives<\/jats:title>\n                    <jats:p>To determine tolerability, overall response rate, time to response, and progression-free survival of horses with biopsy-confirmed or suspected sarcoids treated with ALVAC-fIL2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Client-owned horses with measurable, presumed- or biopsy-confirmed sarcoid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective pilot study. One milliliter of ALVAC-fIL2 was injected into 4 to 5 areas of the sarcoid(s) in each horse (week 0); this treatment was repeated in weeks 1, 3, and 7. Sarcoids were measured at each visit, and response to treatment was determined according to the Response Evaluation Criteria in Solid Tumors for dogs (v1.0). After the final treatment, horses were reassessed and sarcoids remeasured every 3\u00a0months until tumor progression or for a minimum of 1\u2009year if progression was not documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fourteen horses were included. Tumor size decreased in 86% of the horses, and the median time to first response was 89\u2009days (range, 34-406\u2009days). Median time to best response was 211\u2009days (range, 56-406\u2009days), but 3 of the sarcoids still were decreasing in size at the time of final evaluation. The median progression-free interval was not reached. Adverse events were minimal and included transient focal inflammation in 2 horses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Intratumoral injection of ALVAC-fIL2 has promise as a well-tolerated and effective, tissue-sparing treatment for horses with sarcoid tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.16425","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T06:36:14Z","timestamp":1649831774000},"page":"1179-1184","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["ALVAC-fIL2, a feline interleukin-2 immunomodulator, as a treatment for sarcoids in horses: A pilot study"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0590-0801","authenticated-orcid":false,"given":"Corey","family":"Saba","sequence":"first","affiliation":[{"name":"University of Georgia College of Veterinary Medicine Department of Large Animal Medicine and Surgery, , Athens, Georgia,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Eggleston","sequence":"additional","affiliation":[{"name":"University of Georgia College of Veterinary Medicine Department of Large Animal Medicine and Surgery, , Athens, Georgia,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Parks","sequence":"additional","affiliation":[{"name":"University of Georgia College of Veterinary Medicine Department of Large Animal Medicine and Surgery, , Athens, Georgia,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Peroni","sequence":"additional","affiliation":[{"name":"University of Georgia College of Veterinary Medicine Department of Large Animal Medicine and Surgery, , Athens, Georgia,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Sjoberg","sequence":"additional","affiliation":[{"name":"Maggie's Menagerie Veterinary Services , Ila, Georgia,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelbe","family":"Rice","sequence":"additional","affiliation":[{"name":"Maggie's Menagerie Veterinary Services , Ila, Georgia,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Tyma","sequence":"additional","affiliation":[{"name":"University of Georgia College of Veterinary Medicine Department of Large Animal Medicine and Surgery, , Athens, Georgia,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarred","family":"Williams","sequence":"additional","affiliation":[{"name":"University of Georgia College of Veterinary Medicine Department of Large Animal Medicine and Surgery, , Athens, Georgia,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Grosenbaugh","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Animal Health , Athens, Georgia,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Timothy","family":"Leard","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Animal Health , Athens, Georgia,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,1]]},"reference":[{"key":"2026020303574023800_jvim16425-bib-0001","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2460\/javma.242.1.99","article-title":"Cutaneous neoplastic lesions of equids in the central United States and Canada: 3,351 biopsy specimens from 3,272 equids (2000-2010)","volume":"242","author":"Schaffer","year":"2013","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303574023800_jvim16425-bib-0002","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cveq.2013.09.002","article-title":"Sarcoids","volume":"29","author":"Bergvall","year":"2013","journal-title":"Vet Clin North Am Equine Pract"},{"key":"2026020303574023800_jvim16425-bib-0003","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0749-0739(17)30189-X","article-title":"Equine sarcoids","volume":"14","author":"Goodrich","year":"1998","journal-title":"Vet Clin North Am Equine Pract"},{"key":"2026020303574023800_jvim16425-bib-0004","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12917-017-1215-0","article-title":"Topical use of 5% acyclovir cream for the treatment of occult and verrucous equine sarcoids: a double-blinded placebo-controlled study","volume":"13","author":"Haspeslagh","year":"2017","journal-title":"BMC Vet Res"},{"key":"2026020303574023800_jvim16425-bib-0005","first-page":"709","article-title":"Autologous vaccination for the treatment of equine sarcoids: 18 cases (2009-2014)","volume":"56","author":"Rothacker","year":"2015","journal-title":"Can Vet J"},{"key":"2026020303574023800_jvim16425-bib-0006","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2460\/javma.249.3.311","article-title":"Treatment of sarcoids in equids: 230 cases (2008-2013)","volume":"249","author":"Haspeslagh","year":"2016","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303574023800_jvim16425-bib-0007","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/evj.12456","article-title":"Laser surgery as a treatment for histologically confirmed sarcoids in the horse","volume":"48","author":"Compston","year":"2016","journal-title":"Equine Vet J"},{"key":"2026020303574023800_jvim16425-bib-0008","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-3164.2006.00526.x","article-title":"Efficacy of imiquimod 5% cream in the treatment of equine sarcoids: a pilot study","volume":"17","author":"Nogueira","year":"2006","journal-title":"Vet Dermatol"},{"key":"2026020303574023800_jvim16425-bib-0009","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.2042-3306.1995.tb03046.x","article-title":"Iridium-192 interstitial brachytherapy for equine periocular tumors: treatment results and prognostic factors in 115 horses","volume":"27","author":"Theon","year":"1995","journal-title":"Equine Vet J"},{"key":"2026020303574023800_jvim16425-bib-0010","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/vr.159.11.337","article-title":"Treatment of periocular and non-ocular sarcoids in 18 horses by interstitial brachytherapy with iridium-192","volume":"159","author":"Byam-Cook","year":"2006","journal-title":"Vet Rec"},{"key":"2026020303574023800_jvim16425-bib-0011","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/01652176.2016.1204483","article-title":"Clinical course of sarcoids in 61 Franches-Montagnes horses over a 5-7 year period","volume":"36","author":"Berruex","year":"2016","journal-title":"Vet Q"},{"key":"2026020303574023800_jvim16425-bib-0012","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-3-319-53156-4_2","article-title":"Interleukin-2: old and new approaches to enhance immune-therapeutic efficacy","volume":"995","author":"Dhupkar","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"2026020303574023800_jvim16425-bib-0013","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.vetimm.2008.10.317","article-title":"Clinical application of dendritic cells and interleukin-2 and tools to study activated T cells in horses\u2014first results and implications for quality control","volume":"128","author":"Steinbach","year":"2009","journal-title":"Vet Immunol Immunopathol"},{"key":"2026020303574023800_jvim16425-bib-0014","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00262-002-0369-0","article-title":"Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin\/IL-2","volume":"52","author":"Spoormakers","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"2026020303574023800_jvim16425-bib-0015","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12901","article-title":"Intralesional interleukin-2: a novel option to maximize response to systemic immune checkpoint therapy in loco-regional metastatic melanoma","volume":"32","author":"Langan","year":"2019","journal-title":"Dermatol Ther"},{"key":"2026020303574023800_jvim16425-bib-0016","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40425-019-0567-3","article-title":"Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry","volume":"7","author":"Fishman","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026020303574023800_jvim16425-bib-0017","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40425-019-0522-3","article-title":"Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition","volume":"7","author":"Buchbinder","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026020303574023800_jvim16425-bib-0018","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1746-6148-9-155","article-title":"The effect of interleukin-2 on canine peripheral nerve sheath tumors after marginal surgical excision: a double-blind randomized study","volume":"9","author":"Haagsman","year":"2013","journal-title":"BMC Vet Res"},{"key":"2026020303574023800_jvim16425-bib-0019","first-page":"3385","article-title":"Effective treatment of transmissible venereal tumors in dogs with vincristine and IL2","volume":"35","author":"Deno","year":"2015","journal-title":"Anticancer Res"},{"key":"2026020303574023800_jvim16425-bib-0020","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/vde.12941","article-title":"Treatment of equine sarcoids using recombinant poxviruses expressing feline interleukin-2","volume":"32","author":"Loschelder-Ostrowski","year":"2021","journal-title":"Vet Dermatol"},{"key":"2026020303574023800_jvim16425-bib-0021","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/vco.12032","article-title":"Response evaluation criteria for solid tumors in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"13","author":"Nguyen","year":"2015","journal-title":"Vet Comp Oncologia"},{"key":"2026020303574023800_jvim16425-bib-0022","first-page":"417","article-title":"Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1","volume":"14","year":"2012","journal-title":"Vet Comp Oncologia"},{"key":"2026020303574023800_jvim16425-bib-0023","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/jvet.2001.25874","article-title":"Polymerase chain reaction analysis of the surgical margins of equine sarcoids for bovine papilloma virus DNA","volume":"30","author":"Martens","year":"2001","journal-title":"Vet Surg"},{"key":"2026020303574023800_jvim16425-bib-0024","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.2042-3306.1970.tb04145.x","article-title":"Equine sarcoid","volume":"2","author":"Ragland","year":"1970","journal-title":"Equine Vet J"},{"key":"2026020303574023800_jvim16425-bib-0025","first-page":"773","article-title":"Carbon dioxide laser as a surgical instrument for sarcoid therapy\u2014a retrospective study on 60 cases","volume":"38","author":"Carstanjen","year":"1997","journal-title":"Can Vet J"},{"key":"2026020303574023800_jvim16425-bib-0026","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/vr.149.22.665","article-title":"Evaluation of excision, cryosurgery and local BCG vaccination for the treatment of equine sarcoids","volume":"149","author":"Martens","year":"2001","journal-title":"Vet Rec"},{"key":"2026020303574023800_jvim16425-bib-0027","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF00199861","article-title":"Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial","volume":"21","author":"Klein","year":"1986","journal-title":"Cancer Immunol Immunother"},{"key":"2026020303574023800_jvim16425-bib-0028","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1463-5224.2000.00119.x","article-title":"The diagnosis and treatment of periorbital sarcoid in the horse: 445 cases from 1974 to 1999","volume":"3","author":"Knottenbelt","year":"2000","journal-title":"Vet Ophthalmol"},{"key":"2026020303574023800_jvim16425-bib-0029","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.2042-3306.1985.tb02552.x","article-title":"BCG treatment of periocular sarcoid","volume":"17","author":"Lavach","year":"1985","journal-title":"Equine Vet J"},{"key":"2026020303574023800_jvim16425-bib-0030","doi-asserted-by":"crossref","first-page":"xii1","DOI":"10.1093\/annonc\/mdx739","article-title":"Cancer immunotherapy full speed ahead","volume":"28","author":"Melero","year":"2017","journal-title":"Ann Oncol"},{"key":"2026020303574023800_jvim16425-bib-0031","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.coi.2017.01.003","article-title":"Targeting NK-cell checkpoints for cancer immunotherapy","volume":"45","author":"Muntasell","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"2026020303574023800_jvim16425-bib-0032","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40425-018-0495-7","article-title":"Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics","volume":"7","author":"Guo","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026020303574023800_jvim16425-bib-0033","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1016\/j.vaccine.2006.11.066","article-title":"Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform","volume":"25","author":"Poulet","year":"2007","journal-title":"Vaccine"},{"key":"2026020303574023800_jvim16425-bib-0034","first-page":"131","article-title":"Applications of canarypox (ALVAC) vectors in human and veterinary vaccination","volume":"82","author":"Taylor","year":"1994","journal-title":"Dev Biol Stand"},{"key":"2026020303574023800_jvim16425-bib-0035","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/sj.gt.3302124","article-title":"Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2)","volume":"10","author":"Jourdier","year":"2003","journal-title":"Gene Ther"},{"key":"2026020303574023800_jvim16425-bib-0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trivac.2014.11.001","article-title":"Adjuvant immunotherapy of feline injection-site sarcomas with the recombinant canarypox virus expressing feline interleukine-2 evaluated in a controlled monocentric clinical trial when used in association with surgery and brachytherapy","volume":"4","author":"Jas","year":"2015","journal-title":"Trials Vaccinol"},{"key":"2026020303574023800_jvim16425-bib-0037","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood.V90.6.2406","article-title":"Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy","volume":"90","author":"Ferrari","year":"1997","journal-title":"Blood"},{"key":"2026020303574023800_jvim16425-bib-0038","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.tvjl.2018.08.009","article-title":"The clinical diagnosis of equine sarcoids - part 1: assessment of sensitivity and specificity using a multicentre case-based online examination","volume":"242","author":"Koch","year":"2018","journal-title":"Vet J"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.16425","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.16425","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/36\/3\/1179\/66665394\/jvim16425.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/36\/3\/1179\/66665394\/jvim16425.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:58:03Z","timestamp":1770109083000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/36\/3\/1179\/8448942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.16425","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5]]},"published":{"date-parts":[[2022,5,1]]},"assertion":[{"value":"2021-10-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}